Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Impact of Systematic Pharmacokinetic (PK) Profiles in a Cohort of 29 Patients Treated with Conventional and Extended-Half Life (EHL) Products

Teresa Ceglie, Berardino Pollio, Irene Ricca, Maria Messina, Claudia Linari, Mauro Pagliarino

Blood (2019) 134 (Supplement_1): 1123.

https://doi.org/10.1182/blood-2019-132199

Published: 2019

Journal Articles

Efficacy and Safety of Bay 94-9027 Is Sustained for 5 Years: Outcomes in 33 Patients in the Protect VIII Extension Study

Mark T. Reding, MD, Lone Hvitfeldt Poulsen, Liu Tian, Dr, Pal André Holme, PhD MD

Blood (2018) 132 (Supplement 1): 2492.

https://doi.org/10.1182/blood-2018-99-114659

Published: 2018

Journal Articles

Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension

Mark T. Reding, MD, Shadan Lalezari, Dr, Ingrid Pabinger, MD, Monica Maas Enriquez, Dr, Jonathan M. Ducore, MD

Blood (2018) 132 (Supplement 1): 1206.

https://doi.org/10.1182/blood-2018-99-116272

Published: 2018

Journal Articles

Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)

Pratima Chowdary, MD, Lone Hvitfeldt Poulsen, Miguel A Escobar, MD, Susan Kearney, Meera B. Chitlur, MD, Robert Klamroth, Mudi Misgav, Claude Negrier, Wan Hui Ong Clausen, Frank Driessler, Andrea Landorph, Elena Santagostino

Blood (2018) 132 (Supplement 1): 1177.

https://doi.org/10.1182/blood-2018-99-110308

Published: 2018

Journal Articles

Clinical Outcomes of 14-Day Prophylaxis with rFIXFc: Longitudinal Analysis of the B-LONG and B-YOND Study

Amy D. Shapiro, MD, Margareth C Ozelo, MD PhD, K John Pasi, Jingyuan Feng, Bent Winding, Chris Barnowski, Roshni Kulkarni

Blood (2017) 130 (Supplement 1): 3667.

https://doi.org/10.1182/blood.V130.Suppl_1.3667.3667

Published: 2017

Journal Articles

Beyond ABR: High FIX Activity Levels Translate into Clinical Benefits over Standard Prophylaxis

Guy Young, Manuel Carcao, MDMSc, Susan Kearney, MD, Stephanie Valer Seremetis, MD, David L Cooper, MD

Blood (2017) 130 (Supplement 1): 2372.

https://doi.org/10.1182/blood.V130.Suppl_1.2372.2372

Published: 2017

Journal Articles

Immune Tolerance Induction Treatment Is Cost-Effective in Adult Patients with Long-Standing High-Responding Inhibitors

Alessandra Nunes Loureiro Prezotti, MD, Silmara Aparecida De Lima Montalvão, MSc, Cláudia Lorenzato, MD, Andrea Maia Oliveira, MD, Maria do Perpétuo Socorro Vendramini Orletti, Maria Do Rosario Ferraz Roberti, MD, Luiz Ivando Ferreira Filho, MD, Paula Ribeiro Villaça, MD PhD, Erica Okazaki, MD, Samuel de Souza Medina, MD, Margareth Castro Ozelo, MD PhD

Blood (2015) 126 (23): 3530.

https://doi.org/10.1182/blood.V126.23.3530.3530

Published: 2015

Journal Articles

Personalized Prophylaxis with Human-Cl Recombinant FVIII in HA Patients

Robert Klamroth, Toshko Lissitchkov, MD, Luminita Rusen, Olaf Walter, MD MBA, Johann Bichler, PhD, K John Pasi, Andreas Tiede, MD PhD, Sigurd Knaub, PhD

Blood (2015) 126 (23): 547.

https://doi.org/10.1182/blood.V126.23.547.547

Published: 2015

Journal Articles

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

Barbara A. Konkle, Oleksandra Stasyshyn, Pratima Chowdary, David H. Bevan, Tim Mant, Midori Shima, Werner Engl, Jacqueline Dyck-Jones, Monika Fuerlinger, Lisa Patrone, Bruce Ewenstein, Brigitt Abbuehl

Blood (2015) 126 (9): 1078–1085.

https://doi.org/10.1182/blood-2015-03-630897

Published: 2015

Includes: Supplemental data

Journal Articles

New Data on the Safety and Efficacy of Recombinant FXIII in Patients with Congenital FXIII A-Subunit Deficiency

Katsuyuki Fukutake, MD PhD, Manual Carcao, MD, Aida Inbal, MD, Bryce A. Kerlin, MD, Johannes Oldenburg, MD PhD, Anders Rosholm, MSc, PhD, May-Lill Garly, MD PhD, Diane J. Nugent, MD

Blood (2014) 124 (21): 1520.

https://doi.org/10.1182/blood.V124.21.1520.1520

Published: 2014

Journal Articles

ABR, a Novel Inducer Of Transcription Factor C/EBPα, Is Necessary For Myeloid Differentiation and a Prognostic Factor In Acute Myeloid Leukemia

Carolina Yaeko Namasu, MSc, Dennis Gerloff, Alexander Arthur Wurm, Daniela Braeuer-Hartmann, Jens-Uwe Hartmann, Christiane Katzerke, Sebastian Schwind, MD, Nadja Hilger, Stephan Fricke, MD, Dietger Niederwieser, MD, Gerhard Behre, MD

Blood (2013) 122 (21): 3814.

https://doi.org/10.1182/blood.V122.21.3814.3814

Published: 2013

Journal Articles

Systemically Transplanted Human Bone Marrow Mesenchymal Stem Cells Primarily Traffic to Mesenteric Lymph Nodes

Xin Li, PhD, Wen Ling, MS, Sharmin Khan, MS, Yuping Wang, Ph.D., Angela Pennisi, MD, Bart Barlogie, MD, PhD, John Shaughnessy, Jr., PhD, Shmuel Yaccoby, PhD

Blood (2010) 116 (21): 2580.

https://doi.org/10.1182/blood.V116.21.2580.2580

Published: 2010

Journal Articles

The Alternative Breakpoint Region (ABR) of BCL6 Is An Active Transcribed Region in Germinal Center B Cells and May Serve as An Enhancer

Yulei Shen, MD, PhD, Himabindu Ramachandrareddy, Wing C. Chan, Timothy McKeithan

Blood (2008) 112 (11): 4465.

https://doi.org/10.1182/blood.V112.11.4465.4465

Published: 2008

Journal Articles

Cytogenetics in Pediatric MDS - Data of the EWOG-MDS 98 Study.

K. Michalova, H. B. Beverloo, G. Michaelsen, B. Schlegelberger, J. Harbott, O. A. Haas, G. B. Kerndrup, L. Sainati, E. Bergstraesser, H. Hasle, J. Starý, M. Trebo, M. M. Van den Heuvel-Eibrink, M. Zecca, P. Noellke, A. Fischer, C. M. Niemeyer, D. R. Betts

Blood (2005) 106 (11): 4914.

https://doi.org/10.1182/blood.V106.11.4914.4914

Published: 2005

NARROW

Impact of Systematic Pharmacokinetic (PK) Profiles in a Cohort of 29 Patients Treated with Conventional and Extended-Half Life (EHL) Products

Efficacy and Safety of Bay 94-9027 Is Sustained for 5 Years: Outcomes in 33 Patients in the Protect VIII Extension Study

Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension

Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)

Clinical Outcomes of 14-Day Prophylaxis with rFIXFc: Longitudinal Analysis of the B-LONG and B-YOND Study

Beyond ABR: High FIX Activity Levels Translate into Clinical Benefits over Standard Prophylaxis

Immune Tolerance Induction Treatment Is Cost-Effective in Adult Patients with Long-Standing High-Responding Inhibitors

Personalized Prophylaxis with Human-Cl Recombinant FVIII in HA Patients

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

New Data on the Safety and Efficacy of Recombinant FXIII in Patients with Congenital FXIII A-Subunit Deficiency

ABR, a Novel Inducer Of Transcription Factor C/EBPα, Is Necessary For Myeloid Differentiation and a Prognostic Factor In Acute Myeloid Leukemia

Systemically Transplanted Human Bone Marrow Mesenchymal Stem Cells Primarily Traffic to Mesenteric Lymph Nodes

The Alternative Breakpoint Region (ABR) of BCL6 Is An Active Transcribed Region in Germinal Center B Cells and May Serve as An Enhancer

Cytogenetics in Pediatric MDS - Data of the EWOG-MDS 98 Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only